An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)

Inclusion Criteria: 1. Patients over 18 years old; 2. Patients with left ventricular thrombus newly found by body surface ultrasound less than or equal to 3 months before selection, with no limitation on basic diseases; 3. Patients who received standard anticoagulant therapy for less than 4 weeks before enrollment did not use antiplatelet drugs or only used single antiplatelet drugs; 4. The patients voluntarily joined the study and signed the informed consent. Exclusion Criteria: 1. Patients with contraindications to rivaroxaban anticoagulation therapy; 2. Patients with a history of acute pulmonary embolism or deep venous thrombosis within a week need intensive anticoagulant therapy; 3. Patients with history of hemorrhagic stroke within one week; 4. Patients with cardiac benign and malignant tumors; 5. Aspirin and P2Y12 receptor antagonists should be kept; 6. In patients with severe hepatic and renal insufficiency, alanine aminotransferase \> 3 times the upper limit and total bilirubin \> 2 times the upper limit, creatinine clearance rate \< 15ml / min / 1.73m2; 7. The patient's history of intracerebral hemorrhage and active hemorrhage was 8 months; 8. Patients with hematological diseases, hemoglobin \< 100g / L, platelet \< 80 x 10\^9 / L; 9. Women with pregnancy status, planned pregnancy and lactation period; 10. Patients with life expectancy less than 1 year; 11. Patients enrolled in other clinical studies; 12. Other situations considered unsuitable by the researcher. Note: anticoagulant therapy can be given to patients with left ventricular thrombosis combined with hemorrhagic stroke ≥ 4 weeks or recent ischemic stroke / transient ischemic attack according to the specific situation.